Article Sidebar

Submitted
26 July 2017
Accepted
26 July 2017
Published
8 August 2017
Download
PDF
Statistic
Read Counter : 629 Download : 476

Main Article Content

Abstract

The aim of this experimental study was to examine the effect of erythropoietin on rat model and particularly in an ischemia reperfusion (HR) protocol. The effect of that molecule was studied biochemically using blood mean glucose (Gl) levels. Materials and methods: 40 rats of mean weight 247.7 g were used in the study. Gl levels were measured at 60 min (groups A and C) and at 120 min (groups B and D) of reperfusion. Erythropoietin was administered only in groups C and D. Results were that Epo administration non-significantly increased the gl levels by 5.59% +6.46% (p=0.3208). Reperfusion time non-significantly increased the gl levels by 5.63%+6.45% (p=0.4098). However, erythropoietin administration and reperfusion time together produced a non significant combined effect in increasing the gl levels by 4.94%+3.81% (p= 0.1892). Conclusions: Results of this study indicate that erythropoietin administration, reperfusion time, or their interaction non-significantly increase the blood glucose levels in short-term. Opposite bibliographic data are considered more reliable, until a greater sample provide clearer results.

Keywords

ischemia erythropoietin glucose levels reperfusion

Article Details

How to Cite
Tsompos, C., Panoulis, C., Toutouzas, K., Zografos, G., & Papalois, A. (2017). THE ACUTE EFFECT OF ERYTHROPOIETIN ON GLUCOSE LEVELS DURING ISCHEMIA REPERFUSION INJURY IN RATS. Folia Medica Indonesiana, 52(1), 14–18. https://doi.org/10.20473/fmi.v52i1.5199
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Bader A, Pavlica S, Deiwick A, Lotkova H, Kucera O, Darsow K, Bartel S, Schulze M, Lange HA, Cervinkova Z (2011). Proteomic analysis to display the effect of low doses of erythropoietin on rat liver regeneration. Life Sci 89, 827-833
  2. Berridge MV and Tan AS (1995). Interleukin-3 facilitates glucose transport in a myeloid cell line by regulating the affinity of the glucose transporter for glucose: involvement of protein phosphorylation in transporter activation. Biochem J 305, 843-851
  3. Gąsecki D, Rojek A, Kwarciany M, Boutouyrie P, Nyka W, Laurent S, Narkiewicz K (2012). Pulse wave velocity is associated with early clinical outcome after ischemic stroke. Atherosclerosis 225, 348-352
  4. Katz O, Stuible M, Golishevski N, Lifshitz L, Tremblay ML, Gassmann M, Mittelman M, Neumann D (2010). Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine models. J Endocrinol 205, 87-95
  5. Kokot F, Nieszporek T, Wiecek A, Marcinkowski W, Rudka R, Trembecki J (1994). Influence of long-term erythropoietin treatment on insulin, glucagon, pancreatic polypeptide, and gastrin secretion in haemodialysed patients. Nephrol Dial Transplant 9 Suppl 3, 35-39
  6. Lagarto A, Bueno V, Sanchez JA, Couret M, Valdes O, Barzaga P, Lopez R, Guerra I, Gabilondo T, Vega Y, Beausoleil I (2012). Short-term intra-nasal erythropoietin administration with low sialic acid content is without toxicity or erythropoietic effects. Curr Neurovasc Res 9, 233-238
  7. Lee WC, Chen SM, Wu MC, Hou CW, Lai YC, Laio YH, Lin CH, Kuo CH (2006). The role of dehydro-epiandrosterone levels on physiologic acclimatization to chronic mountaineering activity. High Alt Med Biol 7, 228-236
  8. Mulay S and Congote LF (1985). Influence of maternal diabetes in rats on hemoglobin synthesis and uridine uptake by fetal liver cells. Diabetes 34, 212-216
  9. Nakao T, Matsumoto H, Okada T, Han M, Hidaka H, Yoshino M, Shino T, Yamada C, Nagaoka Y (1998). Influence of erythropoietin treatment on hemoglobin A1c levels in patients with chronic renal failure on hemodialysis. Intern Med 37, 826-830
  10. Nardi K, Milia P, Eusebi P, Paciaroni M, Caso V, Agnelli G (2012). Predictive value of admission blood glucose level on short-term mortality in acute cerebral ischemia. J Diabetes Complications 26, 70-76
  11. Salvesen DR, Brudenell JM, Snijders RJ, Ireland RM, Nicolaides KH (1993). Fetal plasma erythropoietin in pregnancies complicated by maternal diabetes mellitus. Am J Obstet Gynecol 168, 88-94
  12. Spaia S, Pangalos M, Askepidis N, Pazarloglou M, Mavropoulou E, Theodoridis S, Dimitrakopoulos K, Milionis A, Vayonas G (2000). Effect of short-term rHuEPO treatment on insulin resistance in haemodialysis patients. Nephron 84, 320-325
  13. Tsompos C, Panoulis C, Toutouzas K (2015b). Efecto agudo de la eritropoyetina en los niveles del hematocrito durante una lesión por hipoxia-reoxigenación en ratas. Prensa Médica Argentina [La] 101, 25-36
  14. Tsompos C, Panoulis C, Toutouzas K, Zografos G, Papalois A (2015a). The effect of erythropoietin on total protein levels during ischemia reperfusion injury in rats. Int J Neurorehabilitation 2, 146
  15. Wang Q, Gorbey S, Pfister F, Höger S, Dorn-Beineke A, Krügel K, Berrone E, Wu L, Korff T, Lin J, Busch S, Reichenbach A, Feng Y, Hammes HP (2011). Long-term treatment with suberythropoietic Epo is vaso- and neuroprotective in experimental diabetic retinopathy. Cell Physiol Biochem 27, 769-782
  16. Yang YM, Liu Y, Zhu J, Tan HQ, Liang Y, Liu LS, Li JD, Zhang Y; China Clinical Trial of Reviparin and Metabolic Modulation in Acute Myocardial Infarction Treatment Evaluation (CREATE) Investigation Group (2010). Impact of first 24 hours mean blood glucose level on the prognosis of hospitalized patients with ST-segment elevation myocardial infarction. Zhonghua Xin Xue Guan Bing Za Zhi 38, 1065-1072